Upstream Bio, Inc. Share Price

Upstream Bio, Inc. Share Price

NASDAQ: UPB | Micro Cap
$2.13
-$0.64 (-22.92%) Last updated on 17 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Upstream Bio, Inc. Stock Performance

Open
$2.79
Prev. Close
$2.77
Circuit Range
N/A
Day Range
$2.12 - $2.79
Year Range
$2.12 - $33.58
Volume
1,54,611
Average Traded
$2.39

Upstream Bio, Inc. Share Price Today

As of 17 November 2026, Upstream Bio, Inc.'s share price is $2.13. The stock opened at $2.79, compared to its previous close of $2.77. During today's trading session, Upstream Bio, Inc.'s share price traded between $2.12 and $2.79, with an average price of $2.46. Over the past 52 weeks, the stock has recorded a high of $33.58 and a low of $2.12. In terms of performance, Upstream Bio, Inc.'s share price has declined by 74.45% over the last six months and is down 92.52% on a year-on-year basis.

Upstream Bio, Inc. Share Price Chart

Line chart of the Upstream Bio, Inc. price trend over the selected period. The price fell overall, ranging from 2.12 to 2.79, ending at 2.13.
$2.12$2.79
L
Show Current Price
H

Upstream Bio, Inc. Stock Fundamentals & Key Indicators

Market Cap
$114.98M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.99
Revenue (TTM)
$2.85B
Return On Equity (TTM)
-70.07%
Profit Margin
-5032.98%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
2.99%

Upstream Bio, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.67$1.03$0.77$0.40
Net Profit-$42.46-$40.59-$39.70-$41.19
Net Profit Margin-6337.31%-3940.78%-5155.84%-10297.50%
Income ChangeN/A4.40%2.19%-3.75%

Upstream Bio, Inc. Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$2.37$2.85
Net Profit-$76.40-$143.44
Net Profit Margin-3223.63%-5032.98%
Income ChangeN/A-87.75%

About Upstream Bio, Inc.

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).

Upstream Bio, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$3.38
$2.12
-37.74%
Oct 2026
$5.18
$3.40
-35.33%
Sep 2026
$6.54
$5.26
-22.46%
Aug 2026
$6.25
$6.79
+7.95%
Jul 2026
$6.95
$6.29
-9.04%
Jun 2026
$8.31
$6.92
-17.24%
May 2026
$9.21
$8.36
-8.89%
Apr 2026
$9.22
$9.17
+2.23%
Mar 2026
$7.58
$8.97
+16.64%
Feb 2026
$31.66
$7.69
-75.25%
Jan 2026
$27.09
$31.07
+14.29%
Dec 2025
$28.32
$27.18
-4.71%

UPB Share Price FAQs